For the year ending 2025-12-31, BIOA had -$165,461K decrease in cash & cash equivalents over the period. -$82,346K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -80,605 |
| Stock-based compensation expense | 11,691 |
| Depreciation expense | 213 |
| Loss on extinguishment of debt | 0 |
| Non-cash interest expense | 163 |
| Non-cash lease expense | 125 |
| (gain) loss from changes in fair value of warrants | 214 |
| Loss on disposal of property and equipment | -23 |
| Accretion of net investment discounts | 1,623 |
| Accounts receivable | 769 |
| Prepaid expenses and other current assets | 1,713 |
| Other assets | -24 |
| Accounts payable | 788 |
| Accrued expenses and other current liabilities | -3,412 |
| Deferred grant income | 0 |
| Deferred revenue | -6,746 |
| Net cash used in operating activities | -81,627 |
| Purchase of property and equipment | 719 |
| Purchases of marketable securities | 154,747 |
| Maturities of marketable securities | 60,250 |
| Net cash used in investing activities | -95,216 |
| Proceeds from series d issuance | 0 |
| Issuance costs paid on series d issuance | 0 |
| Proceeds from initial public offering, net of underwriting discounts and commissions | 0 |
| Issuance costs paid on initial public offering and private placement | 0 |
| Proceeds from issuance of common shares through private placement, net of placement agent fees | 0 |
| Proceeds from issuance of common stock through at-the-market facility, net of commissions | 17,155 |
| Issuance costs paid on at-the market offering | 64 |
| Deferred offering costs paid | 336 |
| Term loan principal payments | 6,000 |
| Proceeds from issuance of common shares upon stock option exercises | 714 |
| Net cash provided by financing activities | 11,469 |
| Effect of changes in exchange rate on cash and cash equivalents | -87 |
| Net increase (decrease) in cash and cash equivalents | -165,461 |
| Cash, cash equivalents and restricted cash at beginning of period | 354,349 |
| Cash and cash equivalents at end of period | 188,888 |
BioAge Labs, Inc. (BIOA)
BioAge Labs, Inc. (BIOA)